CA2671490A1 - Acetaminophen compositions having minimized side effects including reduced hepatotoxicity - Google Patents

Acetaminophen compositions having minimized side effects including reduced hepatotoxicity Download PDF

Info

Publication number
CA2671490A1
CA2671490A1 CA002671490A CA2671490A CA2671490A1 CA 2671490 A1 CA2671490 A1 CA 2671490A1 CA 002671490 A CA002671490 A CA 002671490A CA 2671490 A CA2671490 A CA 2671490A CA 2671490 A1 CA2671490 A1 CA 2671490A1
Authority
CA
Canada
Prior art keywords
acetaminophen
composition
acetylcysteine
blockers
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002671490A
Other languages
English (en)
French (fr)
Inventor
Eric M. Soderling
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2671490A1 publication Critical patent/CA2671490A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002671490A 2006-12-09 2007-12-08 Acetaminophen compositions having minimized side effects including reduced hepatotoxicity Abandoned CA2671490A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US87374306P 2006-12-09 2006-12-09
US60/873,743 2006-12-09
US11/952,556 US20080139654A1 (en) 2006-12-09 2007-12-07 Acetaminophen compositions having minimized side effects including reduced hepatotoxicity
US11/952,556 2007-12-07
PCT/US2007/025167 WO2008073344A1 (en) 2006-12-09 2007-12-08 Acetaminophen compositions having minimized side effects including reduced hepatotoxicity

Publications (1)

Publication Number Publication Date
CA2671490A1 true CA2671490A1 (en) 2008-06-19

Family

ID=39498949

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002671490A Abandoned CA2671490A1 (en) 2006-12-09 2007-12-08 Acetaminophen compositions having minimized side effects including reduced hepatotoxicity

Country Status (13)

Country Link
US (1) US20080139654A1 (enExample)
EP (1) EP2094253A4 (enExample)
JP (1) JP2010513229A (enExample)
KR (1) KR20090089867A (enExample)
CN (1) CN101588797A (enExample)
AU (1) AU2007332812A1 (enExample)
BR (1) BRPI0721216A2 (enExample)
CA (1) CA2671490A1 (enExample)
EA (1) EA200970449A1 (enExample)
IL (1) IL199056A0 (enExample)
MX (1) MX2009006177A (enExample)
WO (1) WO2008073344A1 (enExample)
ZA (1) ZA200904764B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20080187A1 (it) * 2008-02-07 2009-08-08 Velleja Res Srl Formulazioni di amminoacidi per la prevenzione del danno epatico da paracetamolo
US20110014285A1 (en) * 2009-07-15 2011-01-20 Herzenberg Leonore A N-acetyl cysteine compositions and methods to improve the therapeutic efficacy of acetaminophen
TR201007652A2 (tr) * 2010-09-20 2012-04-24 Bi̇lgi̇ç Mahmut Sinerjik etki.
WO2013044085A1 (en) * 2011-09-23 2013-03-28 Subramanian Veerappan Sellappan A solid, edible, chewable laxative composition
WO2014159994A1 (en) * 2013-03-13 2014-10-02 Nbip, Llc Compositions and methods for removing the odor from glutathione when mixed in an aqueous system
US10104882B2 (en) * 2013-04-29 2018-10-23 Montefiore Medical Center Methods and compositions for preventing and treating electrophile-mediated toxicities
ITMI20130874A1 (it) * 2013-05-29 2014-11-30 Zambon Spa Compresse deglutibili di n-acetilcisteina
AU2017208123B2 (en) * 2016-01-11 2022-04-21 Egetis Therapeutics Ab Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions
KR101962518B1 (ko) 2016-09-13 2019-03-26 울산대학교 산학협력단 일산화탄소 또는 일산화탄소 공급체를 유효성분으로 함유하는 아세트아미노펜 유도 간 독성 예방 또는 치료용 조성물
WO2018089400A1 (en) * 2016-11-09 2018-05-17 The Feinstein Institute For Medical Research Iguratimod as an mif inhibitor
KR102813413B1 (ko) 2019-08-27 2025-05-27 주식회사 엘지에너지솔루션 단위셀의 두께측정장치 및 두께측정방법
US11590090B2 (en) * 2019-09-14 2023-02-28 Anzen Pharmaceuticals, LLC Acetaminophen formulation with protection against toxic effects of overdose
EP4238559A1 (en) 2022-03-04 2023-09-06 Centre Hospitalier Universitaire de Caen Normandie Combinations of acetaminophen and n-acetyl cysteine for the treatment of pain and fever

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474757A (en) * 1992-10-16 1995-12-12 Rutgers University Prevention of acetaminophen overdose toxicity with organosulfur compounds
GR1002731B (el) * 1996-10-21 1997-07-04 Uni-Pharma ����� ������ �.�.�.�. ������������ ���������� Φαρμακευτικα ενεσιμα διαλυματα περιεχοντα συνδυασμους παρακεταμολης με αλλες δραστικες ουσιες.
DE19651551C2 (de) * 1996-12-11 2000-02-03 Klinge Co Chem Pharm Fab Opioidantagonisthaltige galenische Formulierung
US6566401B2 (en) * 2001-03-30 2003-05-20 The Board Of Trustees Of The Leland Stanford Junior University N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
US6863901B2 (en) * 2001-11-30 2005-03-08 Collegium Pharmaceutical, Inc. Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration

Also Published As

Publication number Publication date
KR20090089867A (ko) 2009-08-24
ZA200904764B (en) 2012-12-27
CN101588797A (zh) 2009-11-25
JP2010513229A (ja) 2010-04-30
EA200970449A1 (ru) 2009-08-28
MX2009006177A (es) 2009-08-31
EP2094253A4 (en) 2010-02-10
US20080139654A1 (en) 2008-06-12
AU2007332812A1 (en) 2008-06-19
IL199056A0 (en) 2010-03-28
EP2094253A1 (en) 2009-09-02
BRPI0721216A2 (pt) 2014-12-02
WO2008073344A1 (en) 2008-06-19

Similar Documents

Publication Publication Date Title
US20080139654A1 (en) Acetaminophen compositions having minimized side effects including reduced hepatotoxicity
ES2925951T3 (es) Composición que comprende un agente terapéutico y un estimulante respiratorio y métodos para su uso
JPH0733331B2 (ja) ジフェンヒドラミン類を含んで成る鎮痛および抗炎症組成物
JP2010522135A (ja) 医薬組成物
JP2016155853A (ja) ロキソプロフェン含有医薬組成物
Halpern Analgesic drugs in the management of pain
CA2508611C (en) Compositions of non-steroidal anti-inflammatory drugs, decongestants and anti-histamines
KR20050088188A (ko) 상부 호흡기 충혈 치료용 조성물 및 치료 방법
ES2694506T3 (es) Administración de ibuprofeno por vía intravenosa
JP5823746B2 (ja) 医薬組成物
JP2008100924A (ja) 総合感冒薬組み合わせ製剤
BRPI0908988A2 (pt) formulação galênica oral incluindo cetorolaco e vitaminas do complexo b, em que a vitamina b6 está em uma camada externa separada do resto dos princípios ativos
HK1132196A (en) Acetaminophen compositions having minimized side effects including reduced hepatotoxicity
JP4993998B2 (ja) イブプロフェンを含有する医薬組成物
JP2008247823A (ja) 鎮痛用組成物
Rozhkovsky et al. Methodical manual for self-work of students of the Pharmaceutical Faculty of full-time form of study for the licensed test examination” Step-2. Pharmacy”
WO2015069988A1 (en) Treatment of pain in animals
CA2555383A1 (en) Compositions of non-steroidal anti-inflammatory drugs and decongestants or anti-histamines
Ellingson et al. The use of over-the-counter medications by transplant recipients: a guideline
RU2540509C1 (ru) Лекарство
ALJAMALI SURVEY ON
JP2011225555A (ja) ロキソプロフェン及びクレマスチンを含有する医薬組成物
JP2009510158A (ja) 毒物依存症の治療におけるネボグラミンの使用
UA77792U (uk) Застосування комбінованого лікарського препарату як знеболюючого засобу
UA77794U (uk) Комбінований лікарський препарат

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20121210